Loading...
XNASABEO
Market cap228mUSD
Jan 16, Last price  
5.25USD
1D
-0.94%
1Q
-21.29%
Jan 2017
-95.67%
Name

Abeona Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:ABEO chart
P/E
—
P/S
65.21
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
62.26%
Rev. gr., 5y
3.14%
Revenues
4m
+147.52%
549,0000057,000291,000352,000481,0001,848,0004,404,0002,042,000925,0001,040,000889,000837,0002,998,000010,000,0003,000,0001,414,0003,500,000
Net income
-54m
L+70.35%
-10,238,000-1,700,000-12,874,000-21,856,000-17,215,000-17,340,000-7,537,000-2,532,000-10,532,0004,449,000-26,778,000-14,526,000-21,873,000-27,319,000-56,671,000-76,682,000-88,349,000-88,606,000-31,809,000-54,188,000
CFO
-37m
L-14.89%
-9,077,000-7,301,000-1,958,0004,843,000-6,560,000-2,248,000-6,860,000-7,609,000-3,955,0001,000-1,611,000-10,423,000-13,014,000-22,935,000-39,111,000-62,820,000-35,019,000-65,665,000-43,483,000-37,009,000
Dividend
Mar 31, 20000.593 USD/sh
Earnings
Mar 17, 2025

Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
URL
https://abeonatherapeutics.com/
IPO date
Sep 19, 1980
Employees
57
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,500
147.52%
1,414
-52.87%
Cost of revenue
51,700
46,671
Unusual Expense (Income)
NOPBT
(48,200)
(45,257)
NOPBT Margin
Operating Taxes
(7,887)
Tax Rate
NOPAT
(48,200)
(37,370)
Net income
(54,188)
70.35%
(31,809)
-64.10%
Dividends
Dividend yield
Proceeds from repurchase of equity
37,389
20,710
BB yield
-34.91%
-85.53%
Debt
Debt current
1,996
1,773
Long-term debt
9,802
13,481
Deferred revenue
Other long-term liabilities
31,352
23,820
Net debt
(40,428)
(36,895)
Cash flow
Cash from operating activities
(37,009)
(43,483)
CAPEX
(331)
(130)
Cash from investing activities
208
(23,964)
Cash from financing activities
37,057
43,173
FCF
(45,116)
(26,700)
Balance
Cash
52,226
52,149
Long term investments
Excess cash
52,051
52,078
Stockholders' equity
(749,325)
(695,288)
Invested Capital
801,901
753,496
ROIC
ROCE
EV
Common stock shares outstanding
21,380
7,862
Price
5.01
62.66%
3.08
-63.44%
Market cap
107,116
342.38%
24,213
-27.01%
EV
66,688
(12,682)
EBITDA
(45,002)
(40,680)
EV/EBITDA
0.31
Interest
418
736
Interest/NOPBT